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Background: More than one billion human adults worldwide are overweight and, therefore, are at higher risk of 
developing cardiovascular diseases, diabetes, and a variety of other chronic perturbations. Many believe that use 
of natural dietary supplements could aid in the struggle against obesity. So-called "starch blockers" are listed 
among natural weight loss supplements. Theoretically, they may promote weight loss by interfering with the 
breakdown of complex carbohydrates thereby reducing, or at least slowing, the digestive availability of carbo-
hydrate-derived calories and/or by providing resistant starches to the lower gastrointestinal tract.   
Aims: The present research study examines a dietary supplement containing 445 mg of Phaseolus vulgaris extract 
derived from the white kidney bean, previously shown to inhibit the activity of the digestive enzyme alpha 
amylase, on body composition of overweight human subjects. 
Methods: A randomized, double-blinded, placebo-controlled study was conducted on 60 pre-selected, slightly 
overweight volunteers, whose weight had been essentially stable for at least six months. The volunteers were 
divided into two groups, homogeneous for age, gender, and body weight. The test product containing Phaseolus 
vulgaris extract and the placebo were taken one tablet per day for 30 consecutive days before a main meal rich in 
carbohydrates. Each subject’s body weight, fat and non-fat mass, skin fold thickness, and waist/hip/thigh cir-
cumferences were measured. 
Results: After 30 days, subjects receiving Phaseolus vulgaris extract with a carbohydrate-rich, 2000- to 2200-calorie 
diet had significantly (p<0.001) greater reduction of body weight, BMI, fat mass, adipose tissue thickness, and waist,/hip/ 
thigh circumferences while maintaining lean body mass compared to subjects receiving placebo. 
Conclusion: The results indicate that Phaseolus vulgaris extract produces significant decrements in body weight 
and suggest decrements in fat mass in the face of maintained lean body mass. 
Key words: starch blockers, weight loss, obesity, amylase inhibitors, bean extract 
1.  Introduction 
Excess accumulation of body fat (over-
weight/obesity), a chronic disequilibrium between 
food consumption and energy expenditure, is becom-
ing noticeably more prevalent [1-4]. This is unfortu-
nate for more reasons than just poor physical appear-
ance, because the overweight/obesity states increase 
the risk of hypertension, type II diabetes, arthritis, 
elevated circulating cholesterol, cancer, serious hor-
monal imbalances in women that can lead to sterility, 
chronic renal disease, and even dementia and Alz-
heimer’s disease [1, 5-10]. Although it took an inordi-
nate length of time for widespread realization, it is 
now generally recognized that overweight/obesity 
have reached epidemic proportions in the United 
States [11]. Further, this health problem is not limited 
to America, because globally there are over one billion 
overweight adults according to many including the 
World Health Organization (WHO) [12,13].   
Strategies to lose body fat typically involve a 
combination of dietary changes limiting caloric intake, 
increased physical activity, behavioral therapy, phar-
macotherapy, and, in extreme cases, surgery [1]. Al-
though the availability and popularity of natural die-
tary supplements intended to help with weight loss 
has risen dramatically in recent years, their therapeu-
tic effectiveness remains uncertain in many cases. 
Some providers of weight loss products tend to 
over-hype the utility of dietary supplements without 
sufficient evidence, while many academic individuals 
refuse to believe that natural weight-loss products 
have any therapeutic usefulness. Among potentially 
useful supplements to obtain healthy body propor-
tions are those containing "starch blockers," because 
over-consumption of rapidly-absorbed carbohydrates 
is frequently associated with obesity [14]. Theoreti-
cally, starch blockers could promote weight loss by Int. J. Med. Sci. 2007, 4 
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interfering with and/or slowing the breakdown of 
complex carbohydrates, thereby reducing the diges-
tive availability of carbohydrate-derived calories, at 
least early on, and/or favorably influencing the glu-
cose-insulin system [15-20]. Also recent reports sug-
gest the possibility that “resistant starches’ may play 
an important role in body weight loss [21]. 
The present paper reports findings from a ran-
domized, double-blinded, placebo-controlled investi-
gation in which body weight and body fat composi-
tion of generally healthy, overweight human volun-
teers were examined before and after a 30-day oral 
treatment with placebo or a test formula containing a 
starch blocker
 as the principal active ingredient. [Phase 
2 Starch Neutralizer
TM, also known as Phaseolamin 2250
TM 
and Phase2
TM (Pharmachem Laboratories, Inc., NJ)]. 
2.  Methods 
Study Design 
EVIC ITALIA in Rome, Italy performed this 
randomized, double-blinded, placebo-controlled 
study in accordance with the Helsinki Declaration and 
other applicable laws related to the protection of study 
subjects. Volunteers were recruited through a market 
research company in Rome, Italy from a group of in-
dividuals who expressed a willingness to participate 
in such evaluations. Eighty-two subjects, aged from 
20-45, found to be slightly overweight were selected 
initially. Overweight was calculated using the follow-
ing formula: ideal weight (kg) = 100/(100 - % normal 
body fat) x lean mass. After calculating ideal weight, 
the overweight mass was estimated by measured 
body weight – ideal weight. The selection criteria 
listed in Table 1 were used to exclude or include study 
candidates.  
Table 1. Exclusion and Inclusion Criteria 
 
 
Prior to the initiation of study, each subject was 
questioned concerning the above exclusion and inclu-
sion criteria. 
In order to obtain optimal compliance among 
subjects, it was deemed helpful to pre test participants, 
i.e., would a given individual comply by maintaining 
the overall diet and taking one tablet before a meal 
rich in carbohydrates? After providing written in-
formed consent, each volunteer was examined by a 
physician with expertise in nutrition, and given a 
sheet with nutritional recommendations to be fol-
lowed, including a daily intake of complex carbohy-
drates concentrated in one of two main meals (Table 2). 
The study diet provided approximately 2000 to 2200 
calories per day. All volunteers agreed to follow the 
nutritionist’s recommendations. The candidates were 
entered into a 2-week single-blinded, run-in to en-
rollment and randomization. Subjects in this run-in 
period unknowingly received just placebo: the inves-
tigators were aware that participants received inactive 
ingredients.  
Sixty subjects from the original 82 with proven 
body weight stability and deemed to be most compli-
ant with the expected criteria were subsequently se-
lected for the study itself. The chosen participants re-
ported to the Center after 10, 20, and 30 days to have Int. J. Med. Sci. 2007, 4 
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their body weight checked and recorded. The two 
groups took the assigned tablets, one tablet per day 
before the main meal rich in complex carbohydrates 
for 30 consecutive days (Table 2).   
The two provided tablet formulas were identified 
by the sponsor as Blokcal batch D106B (Test) and 
Blokcal batch 1600301 (Placebo). Tablets were identical 
in appearance so that the test and placebo tablets were 
indistinguishable. An envelope containing the sam-
ple’s qualitative-quantitative formulas and the prod-
uct identification key was delivered to the principal 
investigator and kept at the disposal of the researchers 
during the test period for any unexpected circum-
stances. Upon completion of the study, the envelope 
was opened in the presence of a representative of the 
sponsor and of the Principal Investigator, and the 
representative formulas of the samples were identi-
fied.  
Table 2 A general summary of the meal plan used in the current study. 
 Int. J. Med. Sci. 2007, 4 
 
48
Test Products 
The active substance to be tested was an 800-mg 
tablet (Blokcal D106B) containing approximately 
445mg (56% w/w) of Phase 2 Starch Neutralizer lV, a 
dried aqueous extract of the common bean (Phaseolus 
vulgaris). Phase 2 had been standardized to a mini-
mum of 3000 AAlU (alpha-amylase inhibiting units), 
validated by a modified USP method (SOP 110, Rev. 5). 
Other ingredients present in this preparation were 
calcium phosphate (20%), microcrystalline cellulose 
(10%), vitamin B3 (7%), as well as small amounts (3%) 
of various other ingredients, including chromium pi-
colinate (0.5 mg/tablet). Accordingly, each tablet con-
tained roughly 50-60 mcg of elemental chromium per 
serving. 
The control substance was an 800-mg tablet 
(Blokcal 1600301) containing primarily microcrystal-
line cellulose and maltodextrin (45% w/w each). 
Other ingredients included relatively small amounts 
(~3%) of Si/ybum marianum (milk thistle), cacao, silicon 
dioxide, magnesium stearate, and Curcuma longa 
(turmeric) as a coloring agent. 
Measurements 
Body weight and impedance measurements, skin 
echogram, and waist, hip, and thigh circumferences 
were measured at the beginning and end of the 30-day 
treatment phase. BMI was calculated as the body 
weight in kilograms divided by the square of the 
height in meters.   
Bodv Weight and Composition 
Body weights, performed on undressed indi-
viduals, were measured using a calibrated Bodymas-
ter Scale (Rowenta) that also enabled calculation of the 
body composition (fat mass, lean body mass) through 
bioelectric leg-to-leg impedance measurements. The 
patented "foot pad" design sends a low, safe electrical 
current through the body to measure its composition. 
The electrical current passes more easily through lean 
muscle than fat. Body composition is calculated 
mathematically, based upon the speed at which the 
signal passes through the body [22-25].   
Skin Echogram 
A 7 Mhz linear probe and a 100 MP Logic Echo-
graph (GE Medical Systems) was used to examine the 
morphology and thickness (in mm) of subcutaneous 
tissue in areas where adipose tissue tends to accumu-
late, i.e., the abdominal region for men and the right 
trochanter region for women. The accuracy of the Skin 
Echography is reported by the manufacturer to be ± 
one mm. 
Waist. Hip. and Thigh Circumferences 
The respective circumference of the waist, hips, 
and right thigh was measured using a standard 
non-stretchable flexible measuring tape. Temporary 
tattoos were used to identify the area of reference 
from one reading to the next.   
Adverse/Side Effects 
The study staff monitored subjects throughout 
the investigation for the occurrence of any adverse or 
side effects. 
Statistical Analysis 
To minimize differences in beginning values be-
tween subjects, they were stratified into two groups 
very similar in size, age, gender, and body weight dis-
tribution. At completion, data from 30 subjects receiv-
ing the Test supplement and 29 subjects receiving the 
Placebo supplement were available for statistical 
analysis. For each subject, the differences between 
pre-treatment (baseline) and post-treatment (30-day) 
values for each parameter (body weight, lean body 
mass,  etc.)  were calculated. The differences were al-
ways obtained by subtracting the 30-day values from 
the baseline values. A negative difference indicates a 
reduction in the parameter after 30 days. Conversely, 
a positive difference indicates an increase in that pa-
rameter. This approach allowed test variability to re-
main low and the statistical analysis to be more pow-
erful. The differences between pretreatment and 
30-day values in each of the two groups were ana-
lyzed using the paired Student's t-test (intragroup 
analysis). The differences in the deltas between the 
test and placebo group were analyzed by the unpaired 
t-test (intergroup analysis).   
3.  Results 
The Test and Placebo groups were essentially 
comparable in starting age, gender, BMI, weight, fat 
mass, non-fat mass and various body circumferences 
(Table 3). There was a trend for a lesser skin echogram 
in the placebo group. One subject in the Placebo group 
withdrew from the study for unexplained reasons. No 
significant adverse events were reported. 
Table 3. Baseline Measures of the Test and Control Groups 
Outcome  Test 
(N=30) 
Placebo 
 (N=29) 
P Value 
Age (years)  33.7±1.6  34.2±1.6  0.84 
Gender   22F/8M  20F/9M   
BMI (kg/m2) 25.9±2.0  26.0±2.3  0.42 
Weight (kg)  74.1±2.1 73.4±2.4  0.82 
Fat Mass (kg)  23.0±0.8  22.0±0.8  0.39 
Non Fat Mass (kg)    51.2±2.0  51.5±2.0  0.99 
Skin Echogram (mm)    33.1±1.8  28.6±1.7  0.08 
Waist Circumference (cm)  85.3±1.8  87.4±3.1  0.55 
Hip Circumference (cm)  106.4±1.4  106.5±1.5  0.93 
Right Thigh Circumference (cm)  65.8±1.5  65.9±1.7  0.97 
Ave ± SEM is shown with the exception of gender where the ratio is 
given. Values for the listed outcomes are in parentheses. Only in the skin 
echogram was there a trend toward a statistically significant difference. 
 
  The results were examined within each group. 
While all subjects receiving the active supplement 
(Test) experienced some weight loss and reduction in 
fat mass (estimated via bioelectric impedance), adipose 
tissue thickness (via  skin echogram), and waist, hip, 
and thigh circumferences, some participants in the 
placebo group actually showed increases in these pa-
rameters. Examining intragroup analysis of the 
changes in the Test group by the paired t test, the fol-
lowing averages ± SEM were found at the beginning Int. J. Med. Sci. 2007, 4 
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and end of the study respectively: in kilograms --body 
weight 74.1±2.1 vs. 71.2±2.0 (p<0.001); fat mass 
23.0±0.8 vs. 20.6±0.7 (p<0.001) and non-fat mass 
51.2±2.0 vs. 50.6±2.0 (p<0.001); in millimeters -- skin 
echogram 33.1±1.8 vs. 29.3±1.7 (p<0.001); in centime-
ters – waist circumference 85.3±1.8 vs. 82.5±1.7 
(p<0.001), hip circumference 106.4±1.4 vs. 104.9±1.4 
(p<0.001), and right thigh circumference 65.4±1.5 vs. 
64.9±1.5 (p<0.001).   
Examining intragroup analysis of the Control 
group by the paired t test, the following averages ± 
SEM were found at the beginning and end of the 
study respectively: in kilograms --body weight 
73.4±2.4 vs. 73.2±2.4 (p<0.005); fat mass 22.0±0.8 vs. 
21.8±0.8 (p>0.05) and non fat mass 51.5±2.0 vs. 
51.3±2.0 (p<0.02); in millimeters -- skin echogram 
28.6±1.7 vs. 28.0±1.7 (p<0.04); in centimeters – waist 
circumference 87.4±3.1 vs. 87.0±3.1 (p<0.004), hip cir-
cumference 106.5±1.5 vs. 106.4±1.4 (p>0.05), and right 
thigh circumference 65.9±1.7 vs. 65.7±1.7 (p<0.008).   
As Table 4 illustrates, there was a highly signifi-
cant (p<0.001) difference between the Test and Control 
groups after 30 days in all the changes of components 
measured, i.e., the group receiving the Test supple-
ment containing Phaseolus vulgaris extract had much 
greater loss of body weight, fat mass, adipose tissue 
thickness, and waist, hip, and thigh circumference. 
The difference in mean lean body mass loss just 
proved significant (p<0.05). 
Table 4. Effect of Phaseolus vulgaris-containing extract vs. 
control dietary supplement on the body composition of 
overweight subjects 
Measured Parameter  Test (n=30)  Control 
(n=29) 
p-value 
 Body  weight  (kg) 
  
 -2.93  ± 
1.16 
-0.35 ± 0.38 
 
<0.001 
 
Fat mass (kg)    -2.4 ± 0.67  -0.16 ± 0.33 
 
<0.001 
 
  Lean body mass (kg)  -0.53 ±0.45 
 
-0.19 ± 0.17 
 
<0.05 
 
 Waist  circumference 
(cm) 
-2.93 ± 2.13 
 
-0.47 ± 0.39 
 
<0.001 
  
  Hip circumference (cm)  -1.48 ± 0.66 
 
-0.10 ± 0.47 
 
<0.001 
 
 Thigh  (right) 
 circumference  (cm) 
-0.95 ± 0.80 
 
  -0.26 ± 0.46 
 
<0.001 
 
  Adipose tissue thick-
ness 
 (via skin echogram) 
(mm) 
-4.2 ± 6.51 
 
 
-0.66 ± 2.81 
 
 
<0.001 
 
Ave ± SEM is shown. Among various parameters, a comparison of the 
individual changes within groups (30 day values – baseline) was made 
between the test and control groups. The negative values indicate a loss 
from baseline within the group. The significance of the 30-day changes 
between the test and control groups were compared via the unpaired 
Student’s t test and listed in the last column. 
4.  Discussion 
Our results indicate that a test dietary formula 
containing 445 mg Phase 2 Phaseolus vulgaris extract 
taken daily by overweight human subjects concur-
rently with a carbohydrate-rich portion of a 2000- to 
2200-calorie diet is more effective at reducing body 
weight and body fat mass than placebo. Importantly, 
the major weight changes are brought about more by 
fat loss rather than diminution in non-fat body mass 
as indicated by different means: impedance measure-
ments, waist, hip and thigh measurements, and sub-
cutaneous fat measurements. Earlier, Udani et al. [20] 
reported reduced body weights and serum triglyc-
erides in 14 obese adults receiving 1500 mg of Phaseo-
lus vulgaris extract (Phase 2TM) twice daily with meals 
for eight weeks. However, values did not reach statis-
tical significance. The clearer statistical differences 
found in the present study compared to Udani’s ear-
lier report where larger doses of extract were used [20] 
may be due, at least in part, to the care taken to enroll 
subjects who would comply with a strict protocol.   
The purpose of the run-in period was to exclude 
non-adherent subjects. Obviously, the power to detect 
a meaningful difference between the active interven-
tion and control groups would be enhanced by re-
moving non-adherent participants. We accept that the 
ultimately randomized participants will be less repre-
sentative of the general population of patients. Be-
cause the purpose of this trial was to measure efficacy 
of the agent under study, we chose to measure our 
parameters under optimal circumstances. Future 
studies could examine effects under more regular 
conditions to test the overall effectiveness of the 
product [26]. Evidence suggesting strong adherence to 
the present protocol can be gathered from the statisti-
cally significant mass losses noted even in the Placebo 
group relegated to the same caloric-restricted diet as 
the Test group. 
Many published studies concerning methods to 
combat obesity provide only scale weight loss as the 
principal end point. The assumption that scale weight 
loss is synonymous with fat loss, however, is not al-
ways true [26,27]. Scale weight decreases may reflect 
non fat mass loss as much as fat loss. In the present 
study, indications by many different measurements 
are that the weight loss is principally due to loss of fat 
mass. Leg to leg impedance measurements suggest 
this is true. Although not the “gold standard” like 
DEXA [26], perusal of the literature suggests this 
methodology gives a good first approximation [22-25]. 
In addition, the use of echograms to estimate subcu-
taneous adipose tissue and the changes in body cir-
cumference in various locations corroborate the con-
clusions derived from the impedance data.   
Further evidence of significant fat loss can be 
seen in the changes of the calculated body mass index 
(BMI). BMI is a generally accepted marker of obesity 
health risk [28]. The lowest health-risk category is 
among individuals whose BMI’s range from 20-25, 
and the highest risk category is found in individuals 
whose BMI’s exceed 40. A BMI greater than 40, termed 
as “morbid obesity” or clinically severe obesity, affects 
more than 15 million Americans. In the test group, 
BMI was lowered from an initial 25.9±2.0 (SEM) to 
24.9±1.9 (SEM) (p<0.001). The placebo group showed 
no statistical difference from the initial 26.0±2.3 (SEM) 
to 25.9±2.3 (SEM) (p=0.79). Important to our argument, 
BMI is known to significantly relate to fat mass – more 
so than scale weight alone [29]. The marked loss of fat Int. J. Med. Sci. 2007, 4 
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provided in the face of a much lesser changes in 
non-fat mass caused by the Test formula is exactly 
what most nutritionists desire. 
How do the amylase inhibitors work? Before 
crossing the intestinal wall, all complex carbohydrates 
(i.e., starches) must be hydrolyzed to their monosac-
charide units, in most cases glucose [14]. There are 
several enzymes involved in this process: a-amylase 
present in saliva and pancreatic juice, which converts 
complex carbohydrates into oligosaccharides, and 
various other enzymes (maltase, lactase, etc.) present 
in the brush border of the small intestine that convert 
these oligosaccharides to monosaccharides that can 
then be absorbed. Glucose and other monosaccharides 
generated through this process are transported via the 
hepatic portal vein to the liver. Monosaccharides that 
are not immediately utilized for energy are stored for 
future energy needs as glycogen in the liver or as fat 
(triglycerides) in adipose tissue, liver, and plasma [14]. 
We believe the mechanism behind the weight 
loss relies on the reported a-amylase-inhibiting activ-
ity of the Phaseolus vulgaris extract [15-19]. Phaseolus 
vulgaris extract has been shown in vitro to inhibit the 
activity of a-amylase and may help promote weight 
loss by interfering with the digestion of complex car-
bohydrates to simple, absorbable sugars, potentially 
reducing carbohydrate-derived calories [30,31]. Also, 
slowing of the rapid absorption of carbohydrates 
would favorably influence the insulin system that 
could, in turn, lead to lesser fat accumulation [27]. We 
have previously shown in a rat model the ability of 
so-called “carbohydrate blockers” to prevent early 
absorption of rice starch and sucrose and prevent in-
sulin resistance [32].   
There is yet another mechanism that could con-
tribute to the weight loss. Some dietary carbohydrates 
have a physical form that makes them inaccessible to 
a-amylase and, therefore, resistant to digestion in the 
human gastrointestinal tract. These resistant starches 
enter the colon  largely undigested, where they are 
fermented by colonic bacteria to produce short-chain 
fatty acids, carbon dioxide, and methane. Resistant 
starches yield approximately 50 to 80% of the energy 
obtained from glucose, the principal product of 
non-resistant starch digestion [14]. It has been re-
ported that resistant starch consumption promotes 
lipid oxidation [21]. Suffice it to say, starch blockers 
send starch to distal digestive sites where they may 
have effects similar to the resistant starches [21]. 
Although the active formula used in the present 
investigation consisted of many ingredients, we be-
lieve virtually all of the effect on body fat loss derived 
from the bean extract in the preparation. If one pe-
ruses the list of other ingredients, it is apparent that 
only the chromium picolinate could be involved in 
any significant fat loss [33]. Nevertheless, the amount 
of chromium picolinate (0.5 mg/tablet) present in the 
bean extract-containing formula should have had little 
influence on body composition due to the small dos-
ing. The amount of elemental chromium in 0.5 mg of 
chromium picolinate would amount to roughly 50-60 
mcg supplementation per day. Changes in body 
composition measures following chromium picolinate 
use have been seen sporadically in some studies, but 
generally only at dose levels of 200 mcg Cr or greater 
[33-37]. Based on a review of several published human 
studies, Vincent [38] concluded that chromium pi-
colinate supplementation has relatively little effect on 
body composition even if an exercise program is in-
volved when given at larger daily doses than in the 
present study. 
Raw Phaseolus vulgaris beans contain a variety of 
potentially toxic substances. In animals, reduced food 
intake, impaired weight gain, and even deaths have 
been noted. [39,40]. In humans, consumption of raw or 
undercooked kidney beans has been associated with 
transient, often severe gastrointestinal disturbances 
[41,42]. These effects have been largely attributed to 
phytohemagglutinens (PHA) present at high levels in 
raw beans. However, two facts are important here. 
PHA levels can be reduced considerably by cooking, 
and small white navy beans are reported to have neg-
ligible levels compared to colored beans, which pos-
sess high levels of PHA’s. Suffice it to say, the extract 
used in our study (Phase 2TM) is a standardized white 
kidney bean extract prepared using heated processing 
conditions to substantially inactivate hemagglutinat-
ing activity (HA) and trypsin inhibiting activity (TIA) 
while preserving alpha-amylase inhibiting ability. The 
established product is standardized to contain less 
than 3,400 HA units per gram and less than 40 TIA 
units per mg dry weight. 
5.  Conclusion 
The results of this investigation show that, when 
taken daily by overweight human subjects with the 
carbohydrate-rich portion of a 2000- to 2200-calorie 
diet, a dietary formula containing Phaseolus vulgaris 
extract as the major ingredient produced significant 
decreases in body fat while essentially maintaining 
lean body mass. Phaseolus vulgaris extract appears to 
be a safe and effective aid to consider in weight 
loss/maintenance programs. 
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